PKA inhibitor fragment (6-22) amide Acetate

TargetMol
Product Code: TAR-T21674L
Supplier: TargetMol
CodeSizePrice
TAR-T21674L-1mg1mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21674L-2mg2mg£171.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21674L-5mg5mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21674L-10mg10mg£306.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21674L-1mL1 mL * 10 mM (in DMSO)£457.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21674L-25mg25mg£465.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21674L-50mg50mg£646.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21674L-100mg100mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Further Information

Bioactivity:
PKA Inhibitor Fragment (6-22) amide Acetate is a PKA inhibitor with a Ki of 2.8 nM. It can significantly reverse low-level morphine antinociceptive tolerance in mice.
CAS:
T21674L
Formula:
C82H134N28O26
Molecular Weight:
1928.11
Pathway:
Tyrosine Kinase/Adaptors
Purity:
0.993
SMILES:
CC(O)=O.CC[C@H](C)[C@@H](C(N)=O)NC([C@H](C)NC([C@H](CC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC(CNC([C@H]([C@H](O)C)NC([C@H](CCCNC(N)=N)NC(CNC([C@H](CO)NC([C@H](C)NC([C@H]([C@@H](C)CC)NC([C@H](CC1=CC=CC=C1)NC([C@H](CC(O)=O)NC([C@H](C)NC([C@H](CC2=CC=C(O)C=C2)NC([C@H]([C@H](O)C)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Target:
PKA

References

1. Katz BM, et, al. Synthesis, characterization and inhibitory activities of (4-N3[3,5-3H]Phe10)PKI(6-22)amide and its precursors: photoaffinity labeling peptides for the active site of cyclic AMP-dependent protein kinase. Int J Pept Protein Res. 1989 Jun;33(6):439 2. Dalton GD, et, al. Alterations in brain Protein Kinase A activity and reversal of morphine tolerance by two fragments of native Protein Kinase A inhibitor peptide (PKI). Neuropharmacology. 2005 Apr; 48(5): 648-57.